Arkolith/Insider Trading/ZYNE/Form 4

Rosenberger Brian

VP, Commercial & Business Dev.Zynerba Pharmaceuticals, Inc. (ZYNE) · full profile →Form 4 · filed Sep 14, 2023
Net Selling
Open-Market Buys
$0
Open-Market Sells
$9K
Net Open-Market Flow
-$9K
Transactions
2
2 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Sep 13, 2023Sell(S)6K$1.33$9K250K
Sep 12, 2023Grant(A)22K——256K

Transaction Codes

S
Open-market sale
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001062993-23-018021) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML